Abbott Laboratories (ABT)

ABT (NYSE:Health Services) EQUITY
$42.15
pos +0.71
+1.70%
Today's Range: 41.69 - 42.33 | ABT Avg Daily Volume: 9,621,100
Last Update: 09/30/16 - 1:17 PM EDT
Volume: 3,318,861
YTD Performance: -7.73%
Open: $41.74
Previous Close: $41.44
52 Week Range: $36.00 - $46.38
Oustanding Shares: 1,469,995,415
Market Cap: 62,166,106,100
6-Month Chart
TheStreet Ratings Grade for ABT
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 10
Moderate Buy 1 1 1 2
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.60 1.60 1.60 1.63
Latest Dividend: 0.26
Latest Dividend Yield: 2.46%
Dividend Ex-Date: 10/12/16
Price Earnings Ratio: 32.78
Price Earnings Comparisons:
ABT Sector Avg. S&P 500
32.78 28.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.44% 4.91% 25.05%
GROWTH 12 Mo 3 Yr CAGR
Revenue 0.80 -0.50 -0.20
Net Income 93.70 -0.60 -0.24
EPS 96.00 -0.20 -0.08
Earnings for ABT:
EBITDA 4.34B
Revenue 20.41B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.58 $0.66 $2.20 $2.48
Number of Analysts 11 9 14 14
High Estimate $0.59 $0.68 $2.23 $2.57
Low Estimate $0.57 $0.65 $2.19 $2.40
Prior Year $0.54 $0.62 $2.15 $2.20
Growth Rate (Year over Year) 7.58% 6.09% 2.29% 12.57%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
These sectors are full of high-priced, low-growth stocks.
The leadership is quite stark.
The signs that have warned of a possible market reversal only have become more extreme.
Oil began to rebound Wednesday from steep declines earlier this week.
They should wait until the rally appears to be running out of steam in order to go in on the short side.
The M&A activity is an incredible and a welcome sign.
Movement has become difficult after weeks of advances, which suggests a downturn may be near.
This stock is well into overbought territory.

Columnist Conversations

We added this one Monday and mentioned it Tuesday right here in CC, we'll take it off the board. SOLD WDC O...
The market is rebounding nicely after yesteday's sell-off.  Biotech has recaptured half of its three perc...
The Federal Reserve has made it relatively clear that they intend to raise interest rates in the December mee...
The iShares NASDAQ Biotechnology ETF (IBB) has been trading for the last two months in a channel delineated by...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.